Mylan Spooks Investors With Surprise Plans For Higher 2019 Spending
Executive Summary
Investors sold shares in Mylan after its management unexpectedly announced that it would increase sales and marketing expenses significantly in 2019 to boost growth of complex products that are now a much bigger portion of the generic and specialty drugmaker's revenue.
You may also be interested in...
Former Mylan Executive Faces Jail After Pleading Guilty To Insider Trading
A six-year Mylan employee, Dayakar Mallu, is facing up to six years in jail after pleading guilty to insider trading and tax offence charges.
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.